Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGXX Bright Green		$0.05	$0.03 ▼ $0.54	$11.47M	-0.26	360,154 shs	25,935 shs
NBRV Nabriva Therapeutics		$0.00	$1.22 ▼ $8.45	$45.46M	1.53	29,344 shs	N/A
OKYO OKYO Pharma	$2.45 +1.2%	$1.84	$0.81 ▼ $3.11	$82.90M	-0.27	148,484 shs	40,321 shs
ZIVO ZIVO Bioscience	$14.91	$16.20	$5.53 ▼ $22.15	$56.85M	0.02	982 shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGXX Bright Green	0.00%	0.00%	0.00%	0.00%	-82.29%
NBRV Nabriva Therapeutics	0.00%	0.00%	0.00%	0.00%	+4,900.00%
OKYO OKYO Pharma	+1.24%	+3.38%	+32.43%	+81.48%	+107.63%
ZIVO ZIVO Bioscience	0.00%	+4.85%	-5.09%	-12.81%	+129.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	2.5871 of 5 stars	3.5	3.0	0.0	0.0	3.3	1.7	0.0
ZIVO ZIVO Bioscience	0.3285 of 5 stars	0.0	2.0	0.0	0.0	2.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGXX Bright Green	0.00	N/A	N/A	N/A
NBRV Nabriva Therapeutics	0.00	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	185.71% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BGXX, ZIVO, NBRV, and OKYO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/5/2025	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGXX Bright Green	N/A	N/A	N/A	N/A	$0.06 per share	N/A
NBRV Nabriva Therapeutics	$35.59M	0.00	N/A	N/A	$0.10 per share	0.00
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.20) per share	N/A
ZIVO ZIVO Bioscience	$15.85K	3,586.87	N/A	N/A	($0.81) per share	-18.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGXX Bright Green	-$13.13M	-$0.06	N/A	N/A	N/A	N/A	-88.37%	-55.30%	N/A
NBRV Nabriva Therapeutics	-$57.19M	-$19.20	N/A	N/A	N/A	-148.11%	-365.53%	-135.81%	N/A
OKYO OKYO Pharma	-$16.83M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/12/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	8/12/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGXX Bright Green	N/A	N/A	N/A	N/A	N/A
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGXX Bright Green	N/A	0.01	0.01
NBRV Nabriva Therapeutics	0.12	0.85	0.52
OKYO OKYO Pharma	N/A	0.28	N/A
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGXX Bright Green	7.83%
NBRV Nabriva Therapeutics	0.27%
OKYO OKYO Pharma	2.97%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
BGXX Bright Green	62.55%
NBRV Nabriva Therapeutics	1.63%
OKYO OKYO Pharma	40.46%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGXX Bright Green	2	191.17 million	71.59 million	No Data
NBRV Nabriva Therapeutics	70	32.02 million	31.49 million	Not Optionable
OKYO OKYO Pharma	7	33.84 million	20.15 million	Not Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

BGXX, ZIVO, NBRV, and OKYO Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - What's Next?

June 25 at 5:25 AM | marketbeat.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

ZIVO Bioscience (NASDAQ:ZIVO) Stock Price Passes Below 50 Day Moving Average - Here's What Happened

June 17, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Above 50-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Shares Cross Below 50-Day Moving Average - Should You Sell?

May 30, 2025 | marketbeat.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.comM

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGXX, ZIVO, NBRV, and OKYO Company Descriptions

Bright Green NASDAQ:BGXX

Bright Green Corporation focuses on the cultivation, manufacture, and sale of cannabis and cannabis-related products. Its products are used in research, pharmaceutical applications, and affiliated exports. The company was incorporated in 2019 and is based in Grants, New Mexico.

Nabriva Therapeutics NASDAQ:NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.

OKYO Pharma NASDAQ:OKYO

$2.45 +0.03 (+1.24%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.45 +0.00 (+0.04%)

As of 06/27/2025 07:46 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

ZIVO Bioscience NASDAQ:ZIVO

$14.91 0.00 (0.00%)

As of 06/27/2025

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time